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inhibitory factorAbstract Background: Ventilator associated pneumonia (VAP) is a common complication in
intensive care patients. The clinical diagnosis is difﬁcult and a deﬁnite microbiological diagnosis
based on quantitative culture of bronchoalveolar lavage (BAL) ﬂuid is mandatory. Many biological
markers have been studied in an effort to improve the rapidity and performance of current diagnos-
tic procedures in VAP. So, this study was done with the objective to determine the discriminative
power of single or combining multiple biomarkers in bronchoalveolar lavage including soluble trig-
gering receptor expressed on myeloid cells-1 (sTREM-1), soluble urokinase plasminogen activator
receptor (suPAR), and macrophage migration inhibitory factor (MIF) for the diagnosis of bacterial
VAP among patients who were receiving mechanical ventilation.
Patients and methods: This study was conducted in the intensive care units of Chest, Internal
Medicine and Anesthesia Departments, Zagazig University Hospitals, Egypt, between January
and December 2012, 66 adult patients were included who were receiving mechanical ventilation
724 A. Refaat et al.and eligible for BAL for suspected VAP. The microbiology was assessed with quantitative cultures
of BAL obtained within the ﬁrst 6 h after the development of a new pulmonary inﬁltrate on chest
radiography. All patients were divided into: Group 1, ‘‘deﬁnite VAP’’ with positive quantitative
culture results, Group 2, ‘‘indeterminate VAP’’ with negative BAL culture and received new anti-
biotics at least 24 h prior to BAL, and Group 3, ‘‘deﬁnite absence of VAP,’’ with negative BAL cul-
ture and not receiving antibiotics at the time of BAL.
Measurements: Procalcitonin was measured using an ultrasensitive chemiluminometric assay.
CRP was measured using an enzyme immunoassay. Measurements of sTREM-1, suPAR, and
MIF were performed using a Luminex multiplex assay. Two composite markers were constructed;
one including a linear combination of the three best performing markers and another including all
six markers and the area under the receiver operating characteristic curve (AUC) was used to com-
pare their performance and those of the individual markers.
Results: Of the total 66 enrolled patients receiving mechanical ventilation and undergoing BAL
for suspected pneumonia, 20 patients (30.3%) met deﬁnite microbiologic criteria for group 1, 28
patients (42.4%) with indeterminate VAP in group 2, and 18 patients (27.2%) with deﬁnite absent
VAP in group 3. The mean concentrations of all studied biomarkers were not statistically signiﬁcant
when their levels in BAL samples from patients with deﬁnite VAP were compared with either from
deﬁnite absence of VAP or from indeterminate VAP (all p> 0.05). The AUCs for discrimination
between infection of bacterial origin and no infection were 0.83 (95% CI 0.79–0.88) for CRP, 0.77
(95% CI 0.69–0.79) for PCT, 0.72 (95% CI 0.67–0.77) for neutrophils, 0.60 (95% CI 0.83–0.69) for
MIF, 0.68 (95% CI 0.56–0.67) for sTREM-1 and 0.51 (95% CI 0.48–0.59) for suPAR, 0.86
(0.79–0.89|) for the composite three-marker test (CRP, PCT, and neutrophils), and 0.90
(0.83–0.96) for the composite six-marker test. The six-marker test performed signiﬁcantly better
than all of the single markers (P< 0.05 for the three-marker test and CRP and P< 0.001 for
the ﬁve remaining markers).
Conclusions: Single measurements of sTREM-1, suPAR or MIF concentrations in the BAL ﬂuid
of mechanically-ventilated patients with new or progressive inﬁltrates do not enhance identiﬁcation
of VAP. However, combining results from several inﬂammatory markers may signiﬁcantly improve
the ability to differentiate bacterial from nonbacterial infections. Further studies are needed to fully
determine the diagnostic accuracy of these and other biomarkers.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.Introduction
Ventilator-associated pneumonia (VAP) is a serious complica-
tion of mechanical ventilation which increases the patient’s
stay in the ICU and overall length of hospital stay. VAP is de-
ﬁned as inﬂammation of the lung parenchyma attributed to
bacterial infection and occurring 48 h after endotracheal intu-
bation and mechanical ventilation and is considered the most
common cause of new inﬁltrates among patients requiring
mechanical ventilation [1]. However, VAP is difﬁcult to
diagnose in the critically ill patient because of the presence
of underlying cardiopulmonary disorders, the non-speciﬁc
radiological and clinical signs, and the rapid invasion of the
normally sterile lower respiratory tract by microorganisms in
all patients with an endotracheal tube, requiring that coloniza-
tion be differentiated from true infection [2].
Delayed diagnosis and subsequent delay in initiating appro-
priate therapy may be associated with worse outcomes in
patients with VAP; On the other hand, an incorrect diagnosis
may lead to unnecessary long-term use of broad-spectrum
antibiotics that is linked to the emergence and selection of
resistant bacteria. VAP is clinically suspected when a patient
has radiological new or progressive pulmonary inﬁltrates with
fever, leukocytosis or leukopenia, and purulent tracheobron-
chial secretions [3]. However, there are a number of noninfec-
tious causes of fever and pulmonary inﬁltrates making theabove criteria of limited diagnostic value. Several other criteria
have been proposed for improving the clinical criteria for
VAP, including bronchoscopic lower airway sampling with
quantitative cultures, which is the preferred method for
diagnosis of VAP, but microbiological cultures often take
48–72 h to yield results, and cultures can be inﬂuenced by
new antibiotic therapy [4].
Recent studies have outlined a number of biomarkers
including soluble triggering receptor expressed on myeloid
cells-1 (sTREM-1), soluble urokinase-type plasminogen acti-
vator receptor (suPAR), macrophage migration inhibitory fac-
tor (MIF), procalcitonin (PCT), copeptin, C-reactive protein
(CRP), interleukin-1-beta, granulocyte colony-stimulating
factor, surfactant protein D, receptor of advanced glycation
end-products, midregional pro-atrial natriuretic peptide, and
endotoxin or elastin ﬁbers, which have been tested recently
for use in determining the diagnosis of patients with suspected
or conﬁrmed VAP [5].
sTREM-1 is a transmembrane glycoprotein expressed on
neutrophils, macrophages and monocytes that ampliﬁes the
inﬂammatory response. Its expression by the effector cells is
upregulated in tissues infected by different strains of bacteria
[6]. Soluble urokinase plasminogen activator receptor (suPAR)
has recently been recognized as a potential biologic marker of
disease. Numerous observational studies prove that levels of
suPAR in different body ﬂuids are increased with various
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known about the direct biochemical and molecular back-
ground of these observations [7]. Some studies suggested that
suPAR are involved in the recruitment of monocytes and neu-
trophils and other inﬂammatory responses, which might be
mediated by a direct interaction between suPAR, b-integrins
and other chemotactic factors [7]. Correspondingly, macro-
phage migration inhibitory factor (MIF) has emerged recently
as a pivotal regulator of innate immunity that has been impli-
cated in sepsis pathogenesis. Donnelly et al. [8] demonstrated
that MIF is present in increased concentrations in the lungs
of individuals with ARDS, and that alveolar macrophages
are a source of the protein. Those investigators also showed
that MIF augments the secretion of the pro-inﬂammatory
cytokines tumor necrosis factor-alpha (TNF-a) and interleu-
kin-8 (IL-8) from alveolar macrophages.
Globally, the results of studies evaluating the value of bio-
markers in diagnosing VAP are contradictory. Also, due to the
lack of an acceptable gold standard for measurement of these
biomarkers in BAL ﬂuid, the accuracy of these methods in
diagnosing VAP is controversial. Therefore, we performed a
clinical study with the objective to determine the discriminative
power of single or combining multiple biomarkers in broncho-
alveolar lavage including sTREM-1, suPAR, and MIF) for the
diagnosis of bacterial VAP among patients who were receiving
mechanical ventilation.
Patients and methods
The study was conducted in the intensive care units of Chest,
Internal Medicine, and Anesthesia Departments, Zagazig
University Hospitals between January and December 2012,
66 adult patients who were receiving mechanical ventilation
and eligible for BAL for suspected ventilator-associated pneu-
monia were included. For all studied patients, the following
baseline characteristics were recorded at the time of BAL:
age, gender, body temperature, leukocyte count, chest X-ray,
Clinical Pulmonary Infection Score (CPIS) [9], Table 1, previ-
ous use of antimicrobial therapy, and the presence of comorbid
conditions, including COPD, coronary arterial disease (CAD),
congestive heart failure, diabetes mellitus, renal failure, and
malignancy.Table 1 Clinical pulmonary infection score.
Criterion CPIS points
0 1
Temperature (C) P36.1 and <38.4 P38.5 an
Blood leukocytes (·109/l) P4.0 and 6 11.0  1 6 3
 2P 1
band
 3P 1
no di
Tracheal secretions Absence Presence
(color: w
Oxygenation (PaO2 (mmHg)/FiO2) >240 or ARDS
Chest X-ray No inﬁltrate Diﬀuse o
Semi-quantitative tracheal aspirate
culture (cfu/ml)
 1 < 103
 2 No previous culture
Diﬀuse o
P103 anVAP microbiology was assessed with quantitative cultures
of BAL obtained by ﬁberoptic bronchoscopy performed with-
in the ﬁrst 6 h after the development of a new pulmonary inﬁl-
trate on chest radiography of a patient with clinically
suspected pneumonia. The VAP diagnosis was conﬁrmed
when the BAL cultures yielded 10 colony-forming units/mL
[10].
On the basis of clinical, radiological, and microbiological data,
all patients were assigned to one of three groups [2,11]
Group 1, ‘‘Deﬁnite VAP,’’ was comprised of patients with
positive quantitative microbiologic culture results for bacterial
pathogens.
Group 2, ‘‘Indeterminate VAP,’’ included patients with neg-
ative BAL culture results who had received new or changed
antibiotics for at least 24 h prior to BAL sampling.
Group 3, ‘‘Deﬁnite absence of VAP,’’ consisted of patients
with noninfectious diseases (e.g., interstitial lung disease, pul-
monary edema, and ARDS) who had negative BAL culture re-
sults and who were not receiving antibiotics at the time of
BAL.
All cases of BAL were performed bronchoscopically. The
bronchoscope was advanced through the endotracheal tube
to a lung segment corresponding to an area of radiographic
inﬁltrate and then wedged in position. Three aliquots of
50 mL of sterile saline solution were injected through the chan-
nel of the bronchoscope and then re-aspirated using a mucous
extractor yielding the BAL specimen. BAL was performed in
the pulmonary segment corresponding to the radiological
abnormality [12]. Procalcitonin was measured in BAL using
an ultrasensitive chemiluminometric assay (PCT sensitive
LIA; Brahms AG; Hennigsdorf, Germany). CRP was mea-
sured using an enzyme immunoassay (Hitachi Instrument
917; Roche Diagnostics, Rotkreuz, Switzerland) using reagents
(Wako Chemicals GmbH; Neuss, Germany. BAL leukocyte
and neutrophil counts were measured using the Avida 120 de-
vice (Bayer Diagnostics, Tarrytown, NY, USA). Measure-
ments of suPAR, sTREM-1 and MIF were performed using
a Luminex (Luminex corp. Austin, TX, USA) multiplex assay
[21]. Margins of error for suPAR, sTREM-1 and MIF mea-
surements are 10%, 12% and 13%, respectively.2
d <38.9 636 andP 39
.9
1.1 and absence of
forms
1.1 and 6 17.0,
fferentiation done
 4P 11.1 and presence of band forms
 5P 17.0, no differentiation done
and non-purulence
hite or light yellow)
Presence and non-purulence
(color: yellow, green or brown)
<240 or ARDS
r patchy inﬁltrate Localized inﬁltrate
r patchy culture inﬁltrate
d 61003
>1003
Table 2 Baseline clinical characteristics between the three patient groups.
Characteristics Deﬁnite VAP Indeterminate VAP Deﬁnite absence of VAP P-Value
No. (%) (66) 20 (30.3%) 28 (42.4%) 18 (27.2%) –
Age (mean ± SD) 40 ± 27 y 39 ± 86 y 49 ± 05 y >0.05
Gender (No. (%)) F= 9 (45%)
M= 11 (55%)
F= 17 (60.7%)
M= 11 (39.3%)
F= 8 (44.4%)
M= 10 (55.6%)
>0.05
CIPS (mean ± SD) 217 ± 69 226 ± 84 233 ± 94 >0.05
Co-morbidity (No. (%))
COPD 25(37.8) 9 45 (%) 9 (32.1%) 7 (38.9%) >0.05
CAD 17(25.8) 5 (25%) 4 (14.3%) 8 (44.4%) >0.05
CHF 17(25.8) 7 (35%) 8 (28.6%) 2 (11.1%) >0.05
DM 17(25.8) 5 (25%) 8 (28.6%) 4 (22.2%) >0.05
ESRD 7(10.6) 0 (0%) 2 (7%) 6 (33.3%) >0.05
ESLD 8(12.1) 2 (1%) 4 (14.3%) 2 (11.1%) >0.05
Tracheostomy 9(13.6) 4 (20%) 2 (7%) 3 (16.7%) >0.05
Malignancy 8(12.1) 3 (15%) 5 (17.9%) 3 (16.7%) >0.05
Table 3 The mean values of different BAL inﬂammatory
biomarkers between different patient groups.
Characteristics Deﬁnite VAP Indeterminate
VAP
Absence
of VAP
No. (%) 20 (30.3%) 28 (42.4%) 18 (27.2%)
CRP (mg/mL) 69.5 ± 75 64.1 ± 67 59.1 ± 54
PCT (lg/mL) 1.8 ± 0.7 1.0 ± 1.9 0.2 ± 4.9
Neutrophils (%) 54.1 ± 30 44.2 ± 12.2 40.5 ± 10.9
sTREM-1 (pg/mL) 328 ± 512 218 ± 702 142 ± 654
suPAR (ng/mL) 6.1 ± 9.2 4.4 ± 0.7 3.8 ± 1.5
MIF (ng/mL) 38.7 ± 50 46.4 ± 52 31.4 ± 72
Values as mean ± SD.
All P> 0.05 deﬁnite VAP compared to the absence of VAP.
All P> 0.05 indeterminate VAP compared to the absence of VA.
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Measurements of suPAR, sTREM-1, MIF, CRP and PCTwere
transformed using the logarithmic function in order to obtain
normality of distribution within disease groups. Continuous
variables were compared using Student’s t test for normally dis-
tributed variables and the Mann–Whitney U test for nonnor-
mally distributed variables. The chi-squared test or Fisher’s
exact tests were used to compare categorical variables. Sensitiv-
ities and speciﬁcities with precise 95% conﬁdence intervals (CIs)
were calculated for all single and composite markers. Informa-
tion from the three single best performing markers and all six
markers were combined using the method reported by Xiong
et al. [13], that is, by identifying the linear combination of mark-
ers that yielded the greatest area under the receiver operating
characteristic (ROC) curve (AUC). This led to the construction
of a composite threemarker test and a composite six-marker test
optimized to differentiate between bacterial and nonbacterial
causes of inﬂammation. The diagnostic performances of the
composite markers were compared with the performances of
all single markers using the AUC. For all analyses, p
value < 0.05 was considered statistically signiﬁcant and p
value < 0.001 was considered highly statistically signiﬁcant.
Statistical analyses were performed using SPSS, Version 11.0
for Windows (SPSS, Inc.; Chicago, IL). The three-marker test
was calculated as 0.160 · neutrophil count + 0.981 · log
(CRP) + 0.107 · log(PCT) and six-marker test as 0.551 ·
log(suPAR) + 0.254 · log(sTREM-1) +0.416 · log(MIF) +
0.098 · neutrophils + 0.639 · log(CRP) + 0.201 · log(PCT)
[14].
Results
In this study, 66 patients were included, who were receiving
mechanical ventilation and undergoing BAL for the evaluation
of new or progressive pulmonary inﬁltrates. The baseline char-
acteristics of all studied groups are shown in Table 2. We
found that 42.4% (28 of 66 patients) had been initiated on
new antibiotics for at least 24 h prior to BAL with negative
culture results and were classiﬁed as indeterminate for the
diagnosis of VAP. Twenty patients (30.3%) had positive quan-
titative bacterial BAL culture results and were classiﬁed as def-
inite VAP, and 18 patients (27.3%) had negative culture resultswhile not receiving antibiotics and were classiﬁed as deﬁnite
absence of VAP. Table 2 showed that there were no signiﬁcant
differences between different patient groups regarding baseline
clinical characteristics or associated co-morbidities, (all
p> 0.05).
Table 3 showed the mean and standard deviation (SD), for
PCT and CRP in BAL samples obtained from patients with
deﬁnite VAP and those without VAP (PCT; 1.8 ± 0.7 vs.
0.6 ± 4.9; p> 0.05) and (CRP; 69.5 ± 75 vs. 59.1 ± 54;
p> 0.05). No signiﬁcant differences were found between both
groups. From this table also, it is clear that there were
non-signiﬁcant differences between deﬁnite VAP and indeter-
minate VAP groups (PCT; 1.8 ± 0.7 vs. 1.0 ± 1.9; p> 0.05)
and (CRP; 69.5 ± 75 vs. 64.1 ± 67; p> 0.05). The percent
of neutrophils in BAL ﬂuid was also not statistically different
in patients with deﬁnite VAP than in those with a deﬁnite ab-
sence of VAP (54.1 ± 30 vs. 40.5 ± 10.9; p> 0.05), and sim-
ilarly when comparing patients with deﬁnite VAP and
indeterminate VAP (54.1 ± 30 vs. 44.2 ± 12.2; p> 0.05).
Although the mean sTREM-1 concentration was greater in pa-
tients with deﬁnite VAP (n 20; 287 ± 512 pg/mL) relative to
those with indeterminate VAP (n 218 ± 702 pg/mL) and those
with deﬁnite absence of VAP (n 18; 152 ± 654 pg/mL)
(Table 2), these differences were not statistically signiﬁcant
(p> 0.05). No signiﬁcant differences were found also in
BAL suPAR and MIF levels in deﬁnite VAP patients in
Figure 1 Distribution of different BAL biomarker concentrations according to patient groups. Boxes showed median value and
interquartile range.
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Table 4 Accuracy of the six inﬂammatory markers and the combined three-marker and six-marker tests in diagnosing bacterial
infection in VIP patients.
Biomarker Sensitivity (95% CI) Speciﬁcity (95% CI) AUC (95% CI) Positive predictive value Negative predictive value
CRP 0.80 (0.77–0.85) 0.60 (0.54–0.72) 0.83 (0.79–0.88) 0.86 0.71
PCT 0.77 (0.69–0.82) 0.59 (0.52–0.68) 0.77 (0.69–0.79) 0.80 0.62
Neutrophil count 0.70 (0.64–0.76) 0.62 (0.57–0.68) 0.72 (0.67–0.77) 0.86 0.55
3-Markers 0.85 (0.72–0.90) 0.75 (0.66–0.86) 0.86 (0.79–0.89) 0.90 0.66
sTREM-1 0.76 (0.66–0.82) 0.62 (0.59–0.68) 0.68 (0.56–0.67) 0.72 0.54
suPAR 0.42 (0.38–0.48) 0.69 (0.67–0.77) 0.51 (0.48–0.59) 0.56 0.38
MIF 0.71 (0.65–0.80) 0.57 (0.51–0.66) 0.60 (0.53–0.69) 0.69 0.58
6-Markers 0.92 (0.83–0.96) 0.79 (0.74–0.84) 0.90 (0.83–0.96) 0.87 0.76
The optimal cutoffs used were 59 mg/l for CRP, 0.28 lg/l for PCT, 8.5 · 109 cells/l for neutrophil count, 50 ng/l for MIF, 200 pg/l for sTREM-1,
4.5 ng/l for suPAR, 6.1 for the three-marker test and 4.1 for the six-marker test.
Figure 2 Receiver operating characteristic (ROC) curves com-
paring the three-marker and six-marker tests and different BAL
biomarker’s ability for the detection of bacterial versus nonbac-
terial causes of VAP.
728 A. Refaat et al.comparison to absent VAP or indeterminate VAP patients
(uPAR; 6.1 ± 9.2 vs. 3.8 ± 1.5; p> 0.05), (MIF; 38.7 ± 50
vs. 31.4 ± 72; p> 0.05) and (suPAR; 6.1 ± 9.2 vs.
4.4 ± 0.7; p> 0.05) and (MIF; 38.7 ± 50 vs. 46.4 ± 52;
p> 0.05) respectively.
In Fig. 1 we compared concentrations of the various mark-
ers between the three patient groups. The respective median
concentrations in deﬁnite VAP group vs. deﬁnite non-VAP
group were as follows: 175 and 70 mg/l (P> 0.05) for CRP,
1.0 and 0.60 lg/l (P> 0.05) for PCT, 13.0 and 6.0 · 109
cells/l (P> 0.05) for neutrophils, 5.0 and 4.8 ng/l (P> 0.05)
for suPAR, 210 and 138 pg/l (P> 0.05) for sTREM-1, and
51.0 and 36.0 ng/l (P> 0.05) for MIF. Likewise, the respective
median concentrations in deﬁnite VAP group vs. deﬁnite non-
VAP group were as follows: 175 and 150 mg/l (P> 0.05) for
CRP, 0.60 and 0.10 lg/l (P> 0.05) for PCT, 13.0 and
9.0 · 109 cells/l (P> 0.05) for neutrophils, 5.0 and 2.8 ng/l
(P> 0.05) for suPAR, 210 and 145 pg/l (P> 0.05) for
sTREM-1, and 51.0 and 56.0 ng/L (P> 0.05) for MIF.
The computed speciﬁcities, sensitivities, positive and nega-
tive predictive values of the single markers and the compositemarkers with regard to diagnosis of deﬁnite VAP are shown in
Table 4. A cutoff value for sTREM-1 in BAL ﬂuid of 200 pg/
mL yielded a diagnostic sensitivity of 76%, speciﬁcity of 62%,
positive predictive value of 72%, and a negative predictive
value of 54% for deﬁnite VAP. When the additional ﬁve mark-
ers were integrating, the sensitivity was increased to 92%, spec-
iﬁcity of 79%, positive predictive value of 87%, and a negative
predictive value of 76% for deﬁnite VAP. Additional analysis
of the ability of single markers to discriminate between infec-
tion of bacterial origin and no infection identiﬁed AUCs of
0.83 (95% CI 0.79–0.88) for CRP, 0.77 (95% CI 0.69–0.79)
for PCT, 0.72 (95% CI 0.67–0.77) for neutrophils, 0.60 (95%
CI 0.83–0.69) for MIF, 0.68 (95% CI 0.56–0.67) for
sTREM-1 and 0.51 (95% CI 0.48–0.59) for suPAR, 0.86
(0.79–0.89 for the composite three-marker test (CRP, PCT,
and neutrophils), and 0.90 (0.83–0.96) for the composite six-
marker test The corresponding ROC curves are shown in
Fig. 2. The six-marker test performed signiﬁcantly better than
all of the single markers (P< 0.05 for three-marker test and
CRP and P< 0.001 for the ﬁve remaining markers).
Discussion
Early identiﬁcation of infections is still a challenge for clini-
cians. The general consensus is not to provide antibiotics for
every suspected infection because of emerging issues with bac-
terial resistance. Therefore, a marker speciﬁc for bacterial
infection will be most helpful. This study found that separate
quantiﬁcation of sTREM-1, suPAR or MIF as single markers
in BAL ﬂuid was not a good predictor of deﬁnite VAP among
ICU patients undergoing evaluation of new or progressive pul-
monary inﬁltrates, however, if they are combined with CRP,
PCT and neutrophil count a high AUC of 0.90 is achieved.
The new in our study that the majority of previous studies
had examined these biomarkers in BAL one at a time, thus
limiting the ability to examine systematically the potential of
multiple markers in combination. We used statistical methods
to identify the linear combination of markers that yield the
greatest AUC.
In general, few studies have investigated the value of
inﬂammatory biomarkers in patients with ventilator associated
pneumonia. The studies that are available show discrepant re-
sults and all focused on the detection of parameters in serum
rather than bronchoalveolar lavage. One of the drawbacks of
detecting any parameter in BAL is the dilution (approximately
10–100 times) of the original ﬂuid present in the alveoli as well
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et al. [15] revealed that rapid detection of sTREM-1 in BAL
ﬂuid can differentiate patients with pneumonia from those
without pneumonia. However, the lack of a gold standard def-
inition for VAP in their study may have hampered the classiﬁ-
cation of some patients. Furthermore, more recent studies
have cast doubt on the overall accuracy of sTREM-1 to detect
pneumonia. Determann et al. [16] found that a cutoff of
200 pg/mL on the day VAP was diagnosed had a sensitivity
of only 75% and a speciﬁcity of 84%, similarly, Horonenko
et al. [17] evaluated sTREM-1 concentrations in BAL ﬂuid
using a sensitive enzyme-linked immunosorbent assay in 14 pa-
tients with VAP and 9 patients without VAP. sTREM-1 was
detected in the BAL ﬂuid of all 14 patients with VAP and in
8 of 9 patients without VAP that did not differ statistically
in the VAP subjects and the non-pneumonia subjects. Our
study supports this observation, suggesting that the use of a
more sensitive assay for the measurement of sTREM-1 concen-
tration alone in BAL ﬂuid may not be able to discriminate be-
tween patients with infection and those with noninfectious
processes accounting for their inﬁltrates.
One interesting work; Huh et al. [18] performed a study in
80 patients with pulmonary inﬁltrates who were classiﬁed as
having either a noninfectious etiology for their inﬁltrates, those
with tuberculosis, viral, or atypical intracellular infection, and
those with extracellular bacterial or fungal pneumonia.
sTREM-1 values were statistically greater in the BAL samples
of patients with extracellular bacterial or fungal infections than
in those of the other groups. They also found that the percent-
age of neutrophils in BAL ﬂuid and CPIS were statistically
greater in patients with proven bacterial and fungal infections.
A concentration of sTREM-1 184 pg/mL in BAL ﬂuid and a
neturophil percentage in BAL ﬂuid 60% were predictive of
bacterial or fungal infection by logistic regression analysis.
At ﬁrst glance, there appears to be a signiﬁcant variance
among the studies measuring sTREM-1 concentration in
BAL ﬂuid for the diagnosis of VAP. The studies by Gibot
et al. [15], and Huh et al. [18], support, at least in part, mea-
surement of BAL concentrations of sTREM-1 as a diagnostic
marker for VAP. Our study and the study by Horonenko et al.
[17] suggest that sTREM-1 measurement in BAL may not be a
reliable diagnostic marker for VAP. Several potential explana-
tions for these discrepant results exist. First, there are differ-
ences in the sensitivity of the assays employed to measure
sTREM-1 concentration among the various studies. Gibot
et al. [15] used an older assay that used old antibody against
sTREM-1. The use of available, newer antibodies appears to
be more sensitive for the measurement of sTREM-1, as also
suggested by Horonenko et al. [17], furthermore due to the im-
mune modulating effects of sTREM-1, its activity may not be
accurately measured, which can result in conﬂicting results.
Our study revealed that both soluble urokinase-type plas-
minogen activator receptor and Macrophage migration inhib-
itory factor could not by themselves differentiate between VAP
and non-VAP cases, however they are valuable as add on
markers to increase the overall sensitivity. suPAR has been re-
ported as a potential biomarker for infectious diseases [19,20].
Sawa et al. [19], studied the role of suPAR as a predictor of
sepsis outcome in a homogenous cohort of 180 patients with
ventilator-associated pneumonia and sepsis and concluded
that suPAR is a reliable marker of sepsis severity and a strong
independent predictor of unfavorable outcome in VAP andsepsis. Yilmaz et al. [21] assessed the abilities of suPAR,
CRP, and PCT to diagnose the patients with SIRS. They
found that suPAR possessed high sensitivity and speciﬁcity
in the diagnosis of Systemic inﬂammatory response syndrome
(SIRS); additionally, high levels were shown to be poorly prog-
nostic. Likewise, Macrophage migration inhibitory factor
(MIF) functions as a pleiotropic protein, participating in
inﬂammatory and immune responses. MIF was originally dis-
covered as a lymphokine involved in delayed hypersensitivity
and various macrophage functions, including phagocytosis,
spreading, and tumoricidal activity [22]. Recently, MIF was
reevaluated as a proinﬂammatory cytokine [23]. However, its
physiologic signiﬁcance remains to be elucidated. One recent
study [24] showed that MIF is a key mediator of host re-
sponses against gram-negative bacteria, acting in part via a
modulation of bacterial killing by macrophages.
Conﬂicting results have been reported for the use of BAL
PCT and CRP as a diagnostic tool for the early onset VAP.
In our study, either BAL PCT or CRP can insigniﬁcantly dif-
ferentiate between patients with and without VAP. In Linssen
et al. [25], 43.6% of patients (51/117) had microbiologically
conﬁrmed VAP. They found no signiﬁcant differences in
PCT and CRP concentrations in serum and BAL ﬂuid between
the VAP and the non-VAP groups. On the contrary, study of
Dele´vaux et al. [26]who checked PCT, CRP, and white blood
cell count in 60 patients with documented bacterial or fungal
infection and 113 patients with bacterial inﬂammatory disease.
They found that PCT values were more discriminative than
WBC and CRP in distinguishing a bacterial infection from
another inﬂammatory process.
In conclusion, our results demonstrated that the single mea-
surements of sTREM-1, suPAR or MIF concentrations in the
BAL ﬂuid of critically ill patients with new or progressive inﬁl-
trates may not enhance the ability of clinicians to identify pa-
tients with VAP. However, combining information from
several inﬂammatory markers may signiﬁcantly improve the
clinician’s ability to differentiate patients with bacterial infec-
tions from those with nonbacterial origin. We suggest that
the major potential advantage of combining biomarkers is
not to diagnose VAP by itself but to potentially improve the
rapidity and performance of current diagnostic procedures.
Further studies are needed to fully determine the diagnostic
accuracy of these and other biomarkers.Conﬂict of interest
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